Tianma Gouteng decoction for essential hypertension
Protocol for a systematic review and meta-analysis

Benjian Chen, MDa, Yuanping Wang, MDb, Zhuogen He, MDa, Dawei Wang, MDa, Xia Yan, MDa,b,*
Pingchang Xie, MDa

Abstract
Background: Essential hypertension is one of the most common chronic diseases, as well as one of the leading risk factors for cardio-cerebrovascular diseases. Tianma Gouteng decoction has been commonly used in clinical practice for patients with essential hypertension. It is important to update the search and evaluation to provide the best available evidence for essential hypertension. Here, we provide a protocol to evaluate the efficacy and safety of Tianma Gouteng decoction (TGD) for essential hypertension.

Methods: Retrieve literature on the TGD treatment for essential hypertension in the databases including PubMed, Cochrane Library, EMBASE, Chinese Biomedical database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang database, and Chinese Science and Technology Periodical database (VIP) on computer. The literature to be collected will be those published from the time when the respective databases were established to January 2018. The therapeutic effects according to the blood pressure (BP) will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed.

Results: This study will provide a high-quality synthesis of current evidence of TGD for essential hypertension from several aspects including BP, life quality, heart rate, and adverse events.

Conclusion: The conclusion of our systematic review will provide evidence to judge whether TGD is an effective intervention for patient with essential hypertension.

PROSPERO registration number: PROSPERO CRD 42018082319.

Abbreviations: ACEI = angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor blockers, CAM = complementary and alternative medicine, CI = confidence interval, MD = mean difference, RCTs = randomized controlled trials, TCM = traditional Chinese medicine, TGD = Tianma Gouteng decoction.

Keywords: essential hypertension, protocol, systematic review, Tianma Gouteng decoction

BC and YW contributed equally to this work and are co-first authors. PX and XY are the guarantor of the article. The manuscript was drafted by BC and YW. ZH and DW developed the search strategy. BC and YW will independently screen the potential studies and extract data. ZH and DW will assess the risk of bias and finish data synthesis. XY will arbitrate any disagreement and ensure that no errors occur during the review. All review authors critically reviewed, revised, and approved the subsequent and final version of the protocol.

This work is supported by Natural Science Foundation of Guangdong Province (No. 2015A030313368 to DW), Guangzhou Municipal Science and Technology Program (No. 201607070337 to XY), and The High-Level Key Disciplines Project of Guangzhou University of Chinese Medicine (No. A1-AFQ18171711089 to DW). The funders had no role in the design, execution, or writing of the study.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

1. Introduction
Essential hypertension is defined as high blood pressure that no secondary cause has been found and the patients diagnosed with the disease have systolic pressure >140 mmHg, or diastolic pressure >90 mmHg. Hypertension is one of the most common chronic diseases, as well as one of the leading risk factors for cardio-cerebrovascular diseases. Their major complications include stroke, myocardial infarction, heart failure, and chronic kidney disease, which not only result in high disability and fatality rate but need great healthcare and social resources input, a heavy burden for both the families and national healthcare system. It is estimated that 1 billion people have high blood pressure worldwide, and about 7.1 million deaths are linked to the disease every year. High blood pressure is becoming increasingly common due to prolonged life expectancy, widespread obesity, reduced physical activity, and unhealthy diets.

Complementary and alternative medicine (CAM) is the term for health therapies and medical products that have typically not been part of conventional medicine and treatments. They may lack a medical explanation and support, however, part of CAM therapies (physical therapy, diet, acupuncture, and traditional Chinese medicine [TCM]) are widely accepted. Today, more patients with cardiovascular disease adopt CAM treatment. TCM is one of the most important parts of CAM, and many studies have shown that Chinese herbal medicine or acupuncture may help control blood pressure.
Scutellaria baicalensis as dizziness and headache, etc. A new animal study shows that it has been used widely in recent decades in China all of which are standardly recorded in Chinese Pharmacopoeia Leonurus japonicus anthes root, Loranthus parasiticus, abalone shell, Gardenia, Leonurus japonicus, caulis polygoni multiflori, and Poria cocos), all of which are standardly recorded in Chinese Pharmacopoeia 2015 edition. It has been used widely in recent decades in China to clinically treat symptoms caused by high blood pressure, such as dizziness and headache, etc. A new animal study shows that TGD could alleviate cognitive dysfunction in rats with hypertension, which was possibly by inducing alteration of glucose metabolism in different brain regions with corresponding functions.

Although only 1 systematic review on the TGD treatment for essential hypertension was published 5 years ago, there has been many high quality randomized controlled clinical studies published in recent years. Therefore, it is important to update the search and evaluation to provide the best available evidence for essential hypertension. Our systematic review and meta-analysis will answer 2 clinical questions about the TGD treatment for the disease: whether TGD is significantly more effective and safer than the traditional antihypertensive drugs or placebo; whether the conventional blood pressure medication assisted by TGD is more effective and safer than using the conventional drugs alone.

2. Methods

2.1. Inclusion criteria for study selection

2.1.1. Types of studies. All randomized controlled trials (RCTs) in both Chinese and English will be included in the research, regardless of whether blinding or allocation concealment was adopted.

2.1.2. Types of patients. The objects of the study will be patients clinically diagnosed with essential hypertension, who have systolic pressure >140mmHg and/or diastolic pressure >90mmHg or take antihypertensive drugs.

2.1.3. Types of interventions. The experimental group used TGD or combined with other conventional antihypertensive drugs, the control group of drugs for conventional antihypertensive drugs or placebo.

2.1.4. Types of outcome measures

2.1.4.1. Primary outcomes. The primary outcome measure was blood pressure.

2.1.4.2. Secondary outcomes.

- Life quality
- Heart rate
- Adverse events

2.2. Search methods for the identification of studies

2.2.1. Electronic searches. Retrieve literature on the TGD treatment for essential hypertension in the databases including PubMed, Cochrane Library, EMBASE, Chinese Biomedical database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang database, and Chinese Science and Technology Periodical database (VIP) on computer. The literature to be collected will be those published from the time when the respective databases were established to January 2018. All references that can meet the inclusion requirements of the study will be reviewed one by one to avoid omission. TGD and essential hypertension will be the search terms. The search strategy of PubMed will be shown in Appendix A, http://links.lww.com/MD/C146 as an example, and similar strategies will be applied to other databases.

2.2.2. Searching other resources. In the meantime, the relevant studies published on journals, along with their references, will be manually reviewed and retrieved as the supplementary literature, http://links.lww.com/MD/C146.

2.3. Data collection and analysis

2.3.1. Selection of studies. Two researchers will independently conduct and cross-check the literature screening. In case of disagreement, they shall discuss with each other to come up with a solution or consult another research member. As for the information unavailable, the reviewers shall contact the author of the original paper. They will read the titles of the references first to exclude the literature that are obviously irrelevant, and then read the abstract and full text to determine whether the studies would be finally included. The process of studies selection is presented in a Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) flow diagram (Fig. 1).

2.3.2. Data collection and management. Two researchers will retrieve the following data independently according to the data collection table designed beforehand: information about the included trials, such as research topic, first author, which journal and when it was published etc., research design and key elements of quality evaluation, information about the patients in the treatment and control group, including how many cases are included and the ages of patients, etc., outcome indicators, relevant indicators of bias risk assessment.

2.3.3. Assessment of risk of bias in included studies. Two evaluators will assess the risks of the included literature using the tool provided by Cochrane Handbook for Systematic Reviews of Interventions V.5.1.0. The tool includes 7 parts, that is, random sequence generation, allocation concealment, blinding method for patients, researchers and outcomes assessors, incomplete result data, and selective reports. The evaluation results will be divided into 3 levels, namely, low-risk, unclear, and high-risk. They will cross-check the evaluation and data retrieval. Where there are inconsistencies, the problem will be resolved through group discussion, or decided by another researcher.

2.3.4. Measures of treatment effect. The study will employ RevMan 5.3 (Version 5.3, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014) to conduct meta-analysis. The rate ratio will be used to indicate the enumeration data while the mean difference (MD) the measurement data. A 95% confidence interval (CI) will be adopted to present the effect sizes.

2.3.5. Dealing with missing data. If the required data are not clear or not reported in clinical papers, the reviewers will collect the missing data with the data collection table by contacting the first or corresponding author of the studies via phone, e-mail, or mail.

2.3.6. Assessment of heterogeneity. The heterogeneity of the results of the included studies will be analyzed through chi-squared test ($\alpha=0.1$), with its value determined by $I^2$. The heterogeneity among the trials will be considered significant if $I^2$ is $>50\%$, and further subgroup analysis will be carried out to investigate the potential causes.
2.3.7. **Assessment of reporting bias.** The visual asymmetry on a funnel plot will be used to judge whether a publication bias exists if at least 10 trials are included in the study.

2.3.8. **Data synthesis.** The meta-analysis will be performed using the fixed effects model if no statistic heterogeneity among the results of the study is found. On the other hand, the random effect model will be employed to carry out the analysis with the effect of the obvious clinical heterogeneity excluded if there is a statistical heterogeneity. When obvious clinical heterogeneity is observed, the researchers can turn to the subgroup or sensitivity analysis, or only descriptive analysis. \( \alpha = 0.05 \) is used to evaluate the meta-analysis.

2.3.9. **Subgroup analysis.** Subgroup analysis will be performed based on different interventions, controls, and outcome measures. Adverse effects will be assessed and tabulated with descriptive techniques.

2.3.10. **Sensitivity analysis.** If \( P \) value of the heterogeneity is \(< .1 \) when the data extraction is examined, and subgroup analysis performed, the meta-analysis will be reducted with the low-quality studies ruled out.

2.3.11. **Ethics and dissemination.** The outcomes of this systematic review will offer implications of the use of TGD treatment for essential hypertension patients. It uses aggregated published data instead of individual patient data and does not require an ethical board review and approval. The findings will be published in a peer-reviewed journal and disseminated in conference presentations. It will provide the latest analysis of the currently available evidence for TGD treating essential hypertension.

3. **Discussion**

Currently, the first-line drugs used in the treatment of essential hypertension include thiazide diuretics, long-acting calcium channel blockers, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin II receptor blockers (ARBs). However, long-term use of these drugs can bring certain side effects to patients, such as headache, facial flush, and other symptoms. TGD may be an alternative to effectively treat essential hypertension with less side effects. Whereas the efficacy and safety of TGD in treating essential hypertension are uncertain. Therefore, it is necessary to conduct a high quality systematic review and meta-analysis, in which our rigorous approach will provide objective evidence for TGD treatment for essential hypertension. The process of performing this systematic review, shown in Fig. 2, will be separated into 4 parts: identification of studies, selection of studies, data extraction and management, and data analysis. Nevertheless, the study may have some limitations. First, only the literature in Chinese and English will be searched, which may lead to language bias. Second, the different doses of TGD adopted in the interventions of the included studies may lead to significant heterogeneity.
Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist of this protocol is presented in online supplementary, http://links.lww.com/MD/C146.

References

[1] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219.

[2] Haspula D, Clark MA. Neuroinflammation and sympathetic overactivity: mechanisms and implications in hypertension. Auton Neurosci 2018; pii: S1566-0702(17)30250-3. doi: 10.1016/j.autneu. 2018.01.002.

[3] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003;290:199–206.

[4] Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension 2017;70:736–42.

[5] Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003;17:471–80.

[6] Singh RB, Suh II, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000;14:749–63.

[7] Bishop FL, Yardley L, Lewith GT. Why consumers maintain complementary and alternative medicine use: a qualitative study. J Altern Complement Med 2010;16:175–82.

[8] Barnes PM, Bloom B, Nahin RL. National Center for Health Statistics (U. S.) Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD:2008.

[9] Kalish LA, Buczynski R, Connell P, et al. Stop hypertension with the acupuncture research program (SHARP): clinical trial design and screening results. Control Clin Trials 2004;25:76–103.

[10] Macklin EA, Wayne PM, Kalish LA, et al. Stop hypertension with the acupuncture research program (SHARP): results of a randomized, controlled clinical trial. Hypertension 2006;48:838–45.

[11] Wang J, Xiong X. Control strategy on hypertension in chinese medicine. Evid Based Complement Alternat Med 2012;2012:284847.

[12] Wang J, Feng B, Yang X, et al. Tiamna gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2013;2013:706125.

[13] Zhang XJ, Sun TC, Liu ZW, et al. Effects of Tianmagouteng particles on brain cognitive function in spontaneously hypertensive rats with hyperactivity of liver-yang: A [F-18] FDG micro-PET imaging study. Biomed Pharmacother 2017;95:1838–43.

[14] Wei H. Effect of tianma gouteng decoction on blood pressure and vascular endothelial function of liver yang syndrome hypertension. J Hubei Univ Tradit Chin Med 2017;19:37–9.

[15] Yang PR, Shih WT, Chu YH, et al. Frequency and co-prescription pattern of Chinese herbal products for hypertension in Taiwan: a Cohort study. BMC Complement Altern Med 2015;15:163.

[16] Carey RM, Whelton PK. Committee AAHGWPrevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med 2018.